CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Gene Kinney

President and Chief Executive Officer, Prothena Corporation plc

Search every verified Gene Kinney interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Gene Kinney, President and CEO of Prothena, has discussed the company’s focus on developing therapies for diseases caused by misfolded proteins, including Alzheimer’s, Parkinson’s, and AL amyloidosis. In interviews from 2023 and 2024, he described Prothena’s pipeline, which includes a monoclonal antibody targeting alpha-synuclein for Parkinson’s disease and partnerships with Roche and Novo Nordisk. He also highlighted the company’s work on an active vaccine targeting amyloid beta and tau proteins, announced in early 2024, and noted progress in biomarker research, particularly the shift toward blood-based biomarkers for Alzheimer’s. Kinney has characterized the current period as an inflection point in neuroscience, citing recent approvals of anti-amyloid treatments and a broader shift from symptom-focused to disease-modifying therapies. He has also commented on the societal burden of age-associated diseases, referencing estimates that Alzheimer’s prevalence could double by 2050 without effective treatments. In earlier remarks from 2020, he discussed Prothena’s financial guidance and collaborations, including a partnership with Bristol-Myers Squibb (formerly Celgene) covering multiple programs.

Recent appearances

  • Will a Focus on Protein Dysregulation Help Prothena Break from the Fold

    August 31, 2024 · 📺 Daniel Levine

    The complexity of neurodegenerative diseases has made it a challenging area for drug developers. Gene Kinney, CEO of Prothena, has long been involved in the pursuit of therapies for diseases such as Alzheimer’s and believes there has been great progress in understanding and targeting these conditions. In fact, he says we are entering a golden age of neuroscience. We spoke to Kinney about the state of drug development for neurodegenerative conditions, Prothena’s pipeline, and its effort to target protein dysregulation in these diseases.

    Watch on YouTube ↗

  • JP Morgan 2024 – Gene Kinney

    January 31, 2024 · 📺 pharmaphorum media limited

    Back at JP Morgan 2023, editor-in-chief Jonah Comstock caught up with Gene Kinney, CEO of Prothena, to learn a little bit about his company’s work on diseases caused by misfolded proteins. This year, they connected again to get an update on Prothena’s phase 3 programme for AL amyloidosis and its various programmes in Alzheimer’s and Parkinson’s, including partnerships with Roche and Novo Nordisk. They also discuss larger trends in the neurological disease space; among them, the recent shift from symptom-focused to disease-altering treatments and what will happen now that Eisai and Biogen’s L…

    Watch on YouTube ↗

  • JP Morgan 2023 – Gene Kinney

    February 15, 2023 · 📺 pharmaphorum media limited

    Outside the JP Morgan Healthcare conference last month, pharmaphorum Editor in Chief Jonah Comstock caught up with Gene Kinney, President and CEO of Prothena Biosciences, to talk about his company, which focuses on protein folding disorders inside and outside the brain.

    Watch on YouTube ↗

  • Prothena Corporation PRTA CEO Gene Kinney on Q4 2019 Results

    February 12, 2020 · 📺 Daily Earnings Calls

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →